NCT lookup

Inclusion Criteria:

* Histologically or cytologically confirmed non-squamous NSCLC.
* Must have evidence of documented pre-existing EGFRm information (EGFRm known to be associated with (epidermal growth factor receptor \[EGFR\] tyrosine kinase inhibitor \[TKis\] sensitivity \[Ex19del, L858R, G719X, S768I, or L861Q\], either alone or in combination with other EGFR mutations, which may include T790M).
* Documented extra-cranial radiologic progression on prior osimertinib monotherapy (as most recent line of treatment) in the adjuvant, locally advanced, or metastatic setting.
* Less than or equal to (\<=2) prior lines of EGFR TKIs (osimertinib is the only permitted prior third generation EGFR TKI).
* At least one lesion, not previously irradiated, that qualifies as a RECIST v1.1 TL at baseline and can be accurately measured at baseline.
* World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate bone marrow reserve and organ function within 7 days before randomization.

Exclusion Criteria:

* Use of chemotherapy, vascular endothelial growth factor inhibitor, immunotherapy or any anti-cancer therapy in the metastatic setting. Platinum-based chemotherapy in non-metastatic setting within 12 months prior to randomization.
* History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 2 years before the first dose of study intervention.
* Any evidence of severe or uncontrolled systemic diseases, including, but not limited to active bleeding diseases, active infection, active ILD/pneumonitis, cardiac disease.
* Has significant third-space fluid retention (example \[eg.\], ascites or pleural effusion) as judged by the investigator and is not amenable for required repeated drainage.
* History of non-infectious ILD/pneumonitis including radiation pneumonitis that required steroids or drug-induced ILD, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
* Has severe pulmonary function compromise resulting from intercurrent pulmonary illnesses.
* Unstable spinal cord compression and/or unstable brain metastases.
* Participants with symptomatic brain metastases (including leptomeningeal involvement).
* Clinically significant corneal disease.
* Uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals, suspected infections or inability to rule out infections. Use of systemic antibiotics within 14 days of randomization.
* Has known human immunodeficiency virus (HIV) infection that is not well controlled.

• Fayetteville, Arkansas, United States
• Duarte, California, United States
• Fountain Valley, California, United States
• La Jolla, California, United States
• Los Angeles, California, United States
• San Diego, California, United States
• Colorado Springs, Colorado, United States
• Fort Collins, Colorado, United States
• Washington D.C., District of Columbia, United States
• Gainesville, Florida, United States
• Jacksonville, Florida, United States
• Athens, Georgia, United States
• Chicago, Illinois, United States
• Evanston, Illinois, United States
• Louisville, Kentucky, United States
• Baltimore, Maryland, United States
• Bethesda, Maryland, United States
• Boston, Massachusetts, United States
• Boston, Massachusetts, United States
• Detroit, Michigan, United States
• Kansas City, Missouri, United States
• Omaha, Nebraska, United States
• Morristown, New Jersey, United States
• Northfield, New Jersey, United States
• New York, New York, United States
• New York, New York, United States
• The Bronx, New York, United States
• Maumee, Ohio, United States
• Philadelphia, Pennsylvania, United States
• Pittsburgh, Pennsylvania, United States
• + 273 more on CT.gov